Prontosan

Phase 3Small molecule

CConsorci Sanitari de l'Alt Penedès i Garraf

Prontosan is one of 5 small molecule programs targeting Skin ulcer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Skin UlcerActive, not recruiting

Skin UlcerPhase 3

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Skin Ulcer

#DrugCompanyPhaseTrials

Inomax

MMallinckrodt

Approved

—2

Viagra

VViatris Specialty LLC

Approved

—3

Prontosan

CConsorci Sanitari de l'Alt Penedès i Garraf

Phase 3

1 4

Allorx

TThe Foundation for Orthopaedics and Regenerative Medicine

Phase 1

1 5

Xiaflex

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Skin Ulcer

NCT06297967

Clinical

Trials by Indication[1]

Skin ulcer1 trial

Acetic Acid 2% Solution for Skin Ulcers

Recruiting·CConsorci Sanitari de l'Alt Penedès i Garraf·Phase 3·NCT06297967·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Prontosan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prontosan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prontosan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Consorci Sanitari de l'Alt Penedès i Garraf company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CConsorci Sanitari de l'Alt Penedès i Garraf

Prontosan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Skin ulcer1 trial

References

Drug Info

Quick Facts

Related News